The spin blocker capacity of borazine is investigated. Specifically, meta-B-B, meta-N-N and para-B-N connected borazines are used as spin-blocker couplers comprised of a pair of radicals: two iminonitroxides (IN); IN and tetrathiafulvalene radical cations (TTF); or two TTFs. Density functional theory (DFT) is used to elucidate the spin blocker capacity of the linkage-specific (meta or para) borazine-coupler and elaborate the role of the lowest unoccupied molecular orbital (LUMO) in magnetic-exchange. Furthermore, a qualitative relation between different magnetic aromaticity indices is made using both nuclear-independent chemical shift (NICS) and the harmonic oscillator model of aromaticity (HOMA). The NICS values are calculated at the centre of the borazine spacer fragment of these diradical species and then also at 0.5 Å increments of the virtual probe from this centre position up to an orthogonal distance of 2.0 Å from the centre. The HOMA values are calculated for the borazine ring fragment in these diradicals. Based on the HOMA and NICS values, it is evident that the borazine exhibits less aromatic character than benzene itself - due to the polar nature of B-N π-bonding. The LUMO mediated spin-exchange between the two consecutive singly occupied molecular orbitals (SOMOs) is explicitly discussed and confirmed to play a pivotal role. The parity of the coupler pathways, i.e. even or odd number of bonds along a selected pathway, between radical moieties is an important factor in predicting the nature and extent of magnetic exchange for these diradicals. Surprisingly, borazine does not always act as a spin-coupling blocker - rather in some cases the coupling is enhanced as compared to a homoatomic (carbon-based) benzene coupler.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/c5cp00801h | DOI Listing |
PLoS One
August 2024
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Background: Social Anxiety Disorder (SAD) is an anxiety disorder characterized by excessive fear of scrutiny in social situations. Health students are more susceptible to SAD due to academic demands. They may resort to self-medication, particularly beta-blockers (BBs) for managing physical symptoms of SAD.
View Article and Find Full Text PDFWorld J Gastroenterol
January 2024
UCL Institute for Liver and Digestive Health, Royal Free Hospital and University College London, London NW3 2PF, United Kingdom.
Portal hypertension (PH) has traditionally been observed as a consequence of significant fibrosis and cirrhosis in advanced non-alcoholic fatty liver disease (NAFLD). However, recent studies have provided evidence that PH may develop in earlier stages of NAFLD, suggesting that there are additional pathogenetic mechanisms at work in addition to liver fibrosis. The early development of PH in NAFLD is associated with hepatocellular lipid accumulation and ballooning, leading to the compression of liver sinusoids.
View Article and Find Full Text PDFCurr Opin Pharmacol
December 2023
School of Biomedical Sciences, The University of Queensland, St Lucia Campus, Brisbane, Queensland, Australia. Electronic address:
Translating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT receptor antagonists evoked pain relief in rodent models of neuropathic pain.
View Article and Find Full Text PDFMol Imaging Biol
June 2024
Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Metabolism
December 2023
Gérontopôle de Toulouse, IHU HealthAge, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, France; CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, Toulouse, France.
Sarcopenia, defined as the loss of muscle mass and function, is a widely prevalent and severe condition in older adults. Since 2016, it is recognized as a disease. Strength exercise training and nutritional support are the frontline treatment of sarcopenia, with no drug currently approved for this indication.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!